论文部分内容阅读
乳腺导管内癌(ductal carcinoma in situ,DCIS)为Gillis在1960年首先描述,近年随着对DCIS认识逐步深入和影像学筛选的广泛应用,其检出率明显增加,国外报道约占全部乳腺癌的15%～20%,我国达到7.8%～18.8%。2003年世界卫生组织正式将DCIS(包括DCIS2MI)归入癌前病变范畴,称为导管上皮内瘤变,认为只有浸润性癌才是真正的乳腺癌。对于导管内癌的治疗,意见还不统一,现就此进行综述,探讨其诊断与治疗方法。
The ductal carcinoma in situ (DCIS) was first described by Gillis in 1960. In recent years, with the gradual deepening of understanding of DCIS and the extensive application of radiological screening, the detection rate of DCIS has been significantly increased, and foreign reports account for about all of breast cancer Of 15% ~ 20%, our country reached 7.8% ~ 18.8%. In 2003, the World Health Organization formally classified DCIS (including DCIS2MI) as precancerous lesions and referred to as ductal intraepithelial neoplasia. Only invasive cancer is considered to be true breast cancer. For the treatment of intraductal cancer, the opinion is not uniform, are now reviewed, to explore its diagnosis and treatment.